

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person Lagan Seamus		2. Issuer Name and Ticker or Trading Symbol Rennova Health, Inc. [RNVA]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) CEO and President	
(Last) (First) (Middle) 400 S. AUSTRALIAN AVE., SUITE 800		3. Date of Earliest Transaction (Month/Day/Year) 07/23/2018			
(Street) WEST PALM BEACH, FL 33401		4. If Amendment, Date Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V		Date Exercisable	Expiration Date						Title
Series J Convertible Preferred Stock	\$ 0.0017 (1)	07/23/2018		A		250,000	07/23/2018	(5)	Common Stock	147,058,824 (2) (3)	\$ 1 (4)	250,000	I	By: Alcimed LLC

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Lagan Seamus 400 S. AUSTRALIAN AVE., SUITE 800 WEST PALM BEACH, FL 33401	X		CEO and President	
Alcimed LLC 400 S. AUSTRALIAN AVE., SUITE 800 WEST PALM BEACH, FL 33401				Affiliated

Signatures

/s/ Seamus Lagan		07/25/2018
<small>**Signature of Reporting Person</small>		Date
Alcimed LLC By: /s/ Seamus Lagan, Sole Manager		07/25/2018
<small>**Signature of Reporting Person</small>		Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) As of July 23, 2018. The conversion price equals the average closing price of the common stock for the 10 trading days prior to the conversion date.
- (2) Based on the conversion price as of July 23, 2018.
- (3) Each share of the Series J Convertible Preferred Stock has the number of votes equal to the number of shares of common stock into which it is convertible, except that, for certain specified matters, through September 30, 2018 only each share has 12,000 votes.
- (4) Alcimed LLC received the shares in exchange for the cancellation of outstanding debt.
- (5) The Series J Preferred Stock will remain outstanding until either converted or redeemed by the Company.

Remarks:

Exhibit List - Exhibit 99 - Joint Filer Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Form 4 - Joint Filer Information

Name: Alcimedede LLC

Address: 400 South Australian Avenue, 8th Floor
West Palm Beach, FL 33401

Designated Filer: Seamus Lagan

Issuer & Ticker Symbol: Rennova Health, Inc. (RNVA)

Date of Earliest Transaction
Required to be Reported
(Month/Day/Year): July 23, 2018

Relationship of Reporting Person to Issuer: Other (Affiliated)

Individual or Joint/Group Filing: Form filed by More than One Reporting Person

Signature: Alcimedede LLC

By: /s/ Seamus Lagan
Seamus Lagan, Sole Manager
